DDO-2213
DDO-2213 is an orally active and potent WDR5-MLL1 inhibitor, with an IC50 of 29 nM and a Kd value of 72.9 nM for the WDR5 protein. DDO-2213 selectively inhibits MLL (mixed lineage leukemia) histone methyltransferase activity and the proliferation of MLL translocation-harboring cells. DDO-2213 can be used for MLL fusion leukemia research[1].
Product Specifications
CAS Number
2378768-36-4
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
WDR5
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ddo-2213.html
Purity
98.84
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=C(C2=CC(NC3=NC=NC(Cl)=C3N)=C(N4CCN(C)CC4)C=C2F)C=C1)N(C)C
Molecular Formula
C24H27ClFN7O
Molecular Weight
483.97
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD79b (B-Cell Marker) (IGB/1843), CF640R conjugate, 0.1mg/mL
